Immuneering Co. to Post FY2024 Earnings of ($1.61) Per Share, Chardan Capital Forecasts (NASDAQ:IMRX)

Immuneering Co. (NASDAQ:IMRX) – Analysts at Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for Immuneering in a note issued to investors on Monday, September 16th. Chardan Capital analyst G. Livshits now expects that the company will post earnings per share of ($1.61) for the year, up from their prior forecast of ($1.64). Chardan Capital currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.90) per share. Chardan Capital also issued estimates for Immuneering’s FY2025 earnings at ($0.75) EPS.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a research note on Friday, September 13th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.60.

Immuneering Stock Performance

NASDAQ IMRX opened at $2.78 on Wednesday. The stock has a 50 day moving average price of $1.26 and a 200-day moving average price of $1.82. Immuneering has a one year low of $1.00 and a one year high of $9.00. The company has a market capitalization of $82.44 million, a P/E ratio of -1.49 and a beta of -0.61.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05.

Institutional Trading of Immuneering

Several institutional investors and hedge funds have recently made changes to their positions in IMRX. Point72 Asia Singapore Pte. Ltd. bought a new stake in Immuneering during the 2nd quarter valued at about $44,000. XTX Topco Ltd grew its stake in Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after acquiring an additional 9,274 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Immuneering during the second quarter worth approximately $67,000. Renaissance Technologies LLC bought a new stake in shares of Immuneering during the second quarter valued at approximately $447,000. Finally, Marshall Wace LLP purchased a new stake in shares of Immuneering in the second quarter valued at approximately $492,000. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.